BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15833373)

  • 1. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.
    Correale J; Rush C; Amengual A; Goicochea MT
    J Neuroimmunol; 2005 May; 162(1-2):173-83. PubMed ID: 15833373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
    Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Sardu C; Russo P; Paolillo A; Mascia M; Solla M; Frau J; Lorefice L; Massole S; Floris G; Marrosu M
    Mult Scler; 2007 Sep; 13(8):975-80. PubMed ID: 17468439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
    Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
    Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
    Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.